Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | GSDMD | P57764 | 2/20 | 0.68 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | PHGDH | O43175 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.36 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ditiocarb SCHEMBL30777192 | 0.83 | ABCB11 (1.00) | ABCB11HTTGSDMDCYP2E1PTGS1 | |
| Ditiocarb SCHEMBL48382 | 0.83 | — | — | |
| Ditiocarb SCHEMBL6064688 | 0.82 | ABCB11 (0.68) | ABCB11HTTGSDMDCYP2E1PTGS1 | |
| SCHEMBL6565171 | 0.81 | ABCB11 (0.40) | ABCB11HTTGSDMDCYP2E1PTGS1 | |
| Ditiocarb SCHEMBL25284941 | 0.80 | ABCB11 (0.94) | ABCB11HTTGSDMDCYP2E1PTGS1 | |
| Ditiocarb SCHEMBL16735397 | 0.80 | — | — | |
| Ditiocarb SCHEMBL81092 | 0.80 | ABCB11 (0.94) | ABCB11HTTGSDMDCYP2E1PTGS1 | |
| Ditiocarb SCHEMBL21359739 | 0.80 | ABCB11 (0.94) | ABCB11HTTGSDMDCYP2E1PTGS1 | |
| Ditiocarb SCHEMBL21801890 | 0.80 | — | — | |
| Ditiocarb SCHEMBL2236180 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-0962537-B1 | Methods for analyzing nucleic acid molecules utilizing sizing techniques | OPERON BIOTECHNOLOGIES INC (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-0992511-B1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES INC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-0868535-B9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7052846-B2 | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques | OPERON BIOTECHNOLOGIES, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-0868535-B2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6815212-B2 | DETECTION OF LIGAND BINDING; OBTAIN SAMPLE, INCUBATE WITH LABEL, SEPARATE BOUND COMPLEXES, REMOVE LABEL, DETECT LABEL BY MASS SPECTROSCOPY | QIAGEN GENOMICS, INC. | 2004-11-09 | — | — | US | disclosed |
| US-20040115694-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | QIAGEN GENOMICS, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-0962537-A2 | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0840804-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | DARWIN MOLECULAR CORPORATION (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027325-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | ABCB11 4811/4885HTT 471/4885GSDMD 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.